These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37221635)

  • 1. The Vestibular Time Constant and Clinical Response to Antimotion Sickness Medication.
    Lagami D; Shupak A; Jamison A; Tal D
    Ear Hear; 2023 Nov-Dec 01; 44(6):1404-1409. PubMed ID: 37221635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vestibular evoked myogenic potentials and motion sickness medications.
    Tal D; Shemy S; Kaminski-Graif G; Wiener G; Hershkovitz D
    Clin Neurophysiol; 2016 Jun; 127(6):2350-4. PubMed ID: 27178852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galvanic vestibular stimulation as a novel treatment for seasickness.
    Gutkovich YE; Lagami D; Jamison A; Fonar Y; Tal D
    Exp Brain Res; 2022 Feb; 240(2):429-437. PubMed ID: 34782915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seasickness susceptibility and the vestibular time constant: a prospective study.
    Lagami D; Gutkovich YE; Jamison A; Fonar Y; Tal D
    Exp Brain Res; 2024 Jan; 242(1):267-274. PubMed ID: 38015244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
    Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness.
    Pingree BJ; Pethybridge RJ
    Aviat Space Environ Med; 1994 Jul; 65(7):597-605. PubMed ID: 7945125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study.
    Gil A; Nachum Z; Tal D; Shupak A
    Clin Neuropharmacol; 2012; 35(1):37-9. PubMed ID: 22139622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical countermeasures have opposite effects on the utricles and semicircular canals in man.
    Weerts AP; De Meyer G; Pauwels G; Vanspauwen R; Dornhoffer JL; Van de Heyning PH; Wuyts FL
    Audiol Neurootol; 2012; 17(4):235-42. PubMed ID: 22517315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of antimotion sickness drugs on habituation to motion.
    Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE
    Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of the semicircular canals via the rotary chair as a means to test pharmacologic countermeasures for space motion sickness.
    Dornhoffer J; Chelonis JJ; Blake D
    Otol Neurotol; 2004 Sep; 25(5):740-5. PubMed ID: 15354005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prokinetic effects of erythromycin after antimotion sickness drugs.
    Stewart JJ; Wood MJ; Parish RC; Wood CD
    J Clin Pharmacol; 2000 Apr; 40(4):347-53. PubMed ID: 10761161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo.
    Klöcker N; Hanschke W; Toussaint S; Verse T
    Eur J Pharm Sci; 2001 May; 13(2):227-32. PubMed ID: 11297908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and duration of intramuscular antimotion sickness medications.
    Wood CD; Stewart JJ; Wood MJ; Mims M
    J Clin Pharmacol; 1992 Nov; 32(11):1008-12. PubMed ID: 1474161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A reduction of vestibulo-visual integration during transdermally administered scopolamine and dimenhydrinate. A presentation of gain control theory in motion sickness.
    Pyykkö I; Schalén L; Jäntti V; Magnusson M
    Acta Otolaryngol Suppl; 1984; 406():167-73. PubMed ID: 6332454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scopolamine (hyoscine) for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2007 Jul; (3):CD002851. PubMed ID: 17636710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Various anti-motion sickness drugs and core body temperature changes.
    Cheung B; Nakashima AM; Hofer KD
    Aviat Space Environ Med; 2011 Apr; 82(4):409-15. PubMed ID: 21485398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.